BC Innovations | Jul 10, 2014
Distillery Therapeutics

Indication: Dermatology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Dermatology Wounds c-Met proto-oncogene (MET; HGFR); hepatocyte growth factor/scatter factor (HGF/SF) In vitro studies suggest allosteric zymogen activator peptides that stimulate MET signaling could help treat...
BC Week In Review | Jul 29, 2013
Company News

Avac Pharma Ltd., ChronTech deal

ChronTech said newco Avac completed its acquisition of all of ChronTech's assets related to development programs for DNA vaccines against HBV and HCV. ChronTech could not be reached for details (see BioCentury, May 13 &...
BC Week In Review | May 27, 2013
Company News

ChronTech infectious, drug delivery news

At its May 16 meeting, ChronTech's shareholders approved the transfer of all of the company's assets related to development programs for DNA vaccines against HBV and HCV to newco Avac Pharma Ltd. for $1 million....
BC Week In Review | May 13, 2013
Company News

ChronTech infectious, drug delivery news

ChronTech said that a group of shareholders offered to acquire all assets related to ChronTech's development programs for DNA vaccines against HBV and HCV for $1 million. The shareholders have formed newco Avac Pharma Ltd....
BC Week In Review | Apr 8, 2013
Clinical News

ChronVac-C: Interim Phase II data

Interim data from an open-label, Swedish Phase II trial in 29 treatment-naive patients with chronic HCV genotype 1 infection showed that 2 doses of 500 µg intramuscular ChronVac-C administered 4 weeks apart followed by Pegasys...
BC Week In Review | Apr 1, 2013
Financial News

ChronTech completes bridge financing

ChronTech Pharma AB (SSE:CTEC), Huddinge, Sweden   Business: Dermatology   Date completed: 3/15/13   Type: Bridge financing   Raised: Not disclosed   Note: The company received the first undisclosed tranche of a $1.3 million bridge...
BC Week In Review | Nov 5, 2012
Company News

ChronTech, Transgene deal

ChronTech said in its interim report for the nine months ending Sept. 30 that a collaboration with Transgene had been terminated. The companies partnered in April 2011 to conduct a Phase I trial to evaluate...
BC Week In Review | Nov 5, 2012
Clinical News

ChronVac-C: Completed Phase IIb enrollment

ChronTech disclosed in its interim results for the first 9 months of 2012, that it completed enrollment of 32 patients in an open-label, Swedish Phase IIb trial evaluating 2 doses of 500 µg intramuscular ChronVac-C...
BC Week In Review | Nov 7, 2011
Financial News

ChronTech amends rights offering

ChronTech Pharma AB (SSE: CTEC), Huddinge, Sweden   Business: Dermatology   Date announced: 10/27/11   Type: Rights offering   To be raised: SEK14.3 million ($2.2 million)   Shares: 46.1 million   Price prior: SEK0.32  ...
BC Innovations | Aug 25, 2011
Targets & Mechanisms

More than one way to stop HCV

A French team led by Epixis S.A. has developed an HCV vaccine that triggers both a T cell response and broadly neutralizing antibodies in macaques. 1 Because of the ability to elicit both types of...
Items per page:
1 - 10 of 92
BC Innovations | Jul 10, 2014
Distillery Therapeutics

Indication: Dermatology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Dermatology Wounds c-Met proto-oncogene (MET; HGFR); hepatocyte growth factor/scatter factor (HGF/SF) In vitro studies suggest allosteric zymogen activator peptides that stimulate MET signaling could help treat...
BC Week In Review | Jul 29, 2013
Company News

Avac Pharma Ltd., ChronTech deal

ChronTech said newco Avac completed its acquisition of all of ChronTech's assets related to development programs for DNA vaccines against HBV and HCV. ChronTech could not be reached for details (see BioCentury, May 13 &...
BC Week In Review | May 27, 2013
Company News

ChronTech infectious, drug delivery news

At its May 16 meeting, ChronTech's shareholders approved the transfer of all of the company's assets related to development programs for DNA vaccines against HBV and HCV to newco Avac Pharma Ltd. for $1 million....
BC Week In Review | May 13, 2013
Company News

ChronTech infectious, drug delivery news

ChronTech said that a group of shareholders offered to acquire all assets related to ChronTech's development programs for DNA vaccines against HBV and HCV for $1 million. The shareholders have formed newco Avac Pharma Ltd....
BC Week In Review | Apr 8, 2013
Clinical News

ChronVac-C: Interim Phase II data

Interim data from an open-label, Swedish Phase II trial in 29 treatment-naive patients with chronic HCV genotype 1 infection showed that 2 doses of 500 µg intramuscular ChronVac-C administered 4 weeks apart followed by Pegasys...
BC Week In Review | Apr 1, 2013
Financial News

ChronTech completes bridge financing

ChronTech Pharma AB (SSE:CTEC), Huddinge, Sweden   Business: Dermatology   Date completed: 3/15/13   Type: Bridge financing   Raised: Not disclosed   Note: The company received the first undisclosed tranche of a $1.3 million bridge...
BC Week In Review | Nov 5, 2012
Company News

ChronTech, Transgene deal

ChronTech said in its interim report for the nine months ending Sept. 30 that a collaboration with Transgene had been terminated. The companies partnered in April 2011 to conduct a Phase I trial to evaluate...
BC Week In Review | Nov 5, 2012
Clinical News

ChronVac-C: Completed Phase IIb enrollment

ChronTech disclosed in its interim results for the first 9 months of 2012, that it completed enrollment of 32 patients in an open-label, Swedish Phase IIb trial evaluating 2 doses of 500 µg intramuscular ChronVac-C...
BC Week In Review | Nov 7, 2011
Financial News

ChronTech amends rights offering

ChronTech Pharma AB (SSE: CTEC), Huddinge, Sweden   Business: Dermatology   Date announced: 10/27/11   Type: Rights offering   To be raised: SEK14.3 million ($2.2 million)   Shares: 46.1 million   Price prior: SEK0.32  ...
BC Innovations | Aug 25, 2011
Targets & Mechanisms

More than one way to stop HCV

A French team led by Epixis S.A. has developed an HCV vaccine that triggers both a T cell response and broadly neutralizing antibodies in macaques. 1 Because of the ability to elicit both types of...
Items per page:
1 - 10 of 92